Our Mission

We are scientists, innovators, trailblazers—and parents. Our mission is personal. We push the boundaries of technology and science to ensure every child, caregiver, and provider has access to early diagnosis and treatment. Because earlier intervention doesn’t just change the moment—it can change a lifetime.

Our Story

It started with a simple goal: understand how children experience the world.

Founder Ami Klin, PhD, was inspired by a bright young man on the autism spectrum facing major social challenges. At Yale, he partnered with Warren Jones, PhD, to develop eye-tracking technology that revealed how children engage with their surroundings—creating the foundation for today’s diagnostic tools.

With support from The Marcus Foundation and the Georgia Research Alliance, that work has evolved into clinically validated tools that help parents and providers tailor treatment to each child’s needs.

How It Started

Back then, eye-tracking research meant lots of screens and bulky equipment.

How It’s Going

Today, it’s all in a simple, easy-to-use device for clinics and families.

Leadership Team

Jamie Pagliaro

PRESIDENT & CEO

Linkedin

Warren Jones, PhD

Scientific Founder
Linkedin

Ami Klin, PhD

Scientific Founder
Linkedin

Cheryl Tierney, MD, MPH

Chief Medical Officer
Linkedin

Leota Pearson

Chief Financial Officer
Linkedin

Pete Polgar

VP of Marketing
Linkedin

Adi Renbaum

VP of Market Access, Health Economics and Reimbursement
Linkedin

John Reviere

VP OF CLINICAL AFFAIRS
Linkedin

Amy Wolbeck

VP OF REGULATORY AFFAIRS
Linkedin

Ryan Bormann

DIRECTOR OF OPERATIONS AND QUALITY
Linkedin

Christopher MacAloon

Executive Vice President of Operations
Linkedin

Board of Directors

Kurt Jacobus

Chairman of the Board

CEO, Restor3D

Jamie Pagliaro

PRESIDENT & CEO

Jim Grien

President & CEO, TM Capital Corp

Jim Adox

Executive Managing Director, Venture Investors

William Marks Jr., MD, MS

Chief Medical Officer, General Partner & Co-Founder, NeuroLaunch Ventures

Neil Hattangadi, MD, MSc

CEO & Co-Founder, Cortica

Using clinically validated measures, we are creating novel technologies that enable parents and providers to know where an individual child is on the spectrum and to tailor treatment for the greatest personal gains. 

QUICK LINKS

EXPLORE

CONTACT

© Copyright 2025 – EarliPoint Health®, Inc | All Rights Reserved | Privacy Policy | Terms
Facebook Youtube Linkedin
Request A Demo

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder